Group 1 - The core viewpoint of the news highlights the current stock performance and valuation metrics of Leksin Medical, indicating a recent increase in stock price and a low rolling PE ratio compared to the industry average [1] - As of August 7, Leksin Medical's stock closed at 16.8 yuan, with a PE ratio of 51.89, marking a new low in 106 days, and a total market capitalization of 3.666 billion yuan [1] - The medical device industry has an average PE ratio of 54.79, with Leksin Medical ranking 87th among its peers [1] Group 2 - Leksin Medical specializes in health IoT and digital health services, producing various smart health monitoring devices [2] - The company has achieved multiple quality certifications, including ISO13485:2016 and ISO9001:2015, and its products have received international certifications such as FDA and CE [2] - In the first quarter of 2025, Leksin Medical reported a revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, reflecting a significant year-on-year growth of 67.88% [2] Group 3 - The PE ratios of Leksin Medical are compared to other companies in the industry, with its TTM PE at 51.89 and static PE at 59.74, alongside a price-to-book ratio of 3.59 [3] - The industry average PE is 54.79, while the median is 37.86, indicating Leksin Medical's valuation is above the median but below the average [3] - The total market capitalization of Leksin Medical is reported at 3.666 billion yuan, positioning it within the competitive landscape of the medical device sector [3]
乐心医疗收盘上涨1.88%,滚动市盈率51.89倍,总市值36.66亿元